ACOG	American College of Obstetricians and Gynecologists
APC	Antigen-Presenting Cell
BRCA	Breast Cancer Gene
BRCAmut	Breast Cancer Gene Mutant
BRCAwt	Breast Cancer Gene Wild Type
bi-shRNA	Bifunctional Short Hairpin
CAR	Chimeric Antigen Receptor
Cerclage	Cervical Suture
CPI	Check-Point Inhibitor
CR3	Conserved Region 3
C + P	Cisplatin plus Paclitaxel
C + T	Cisplatin in Combination with Topotecan
DCs	Dendritic Cells
ENTPD1	Ectonucleoside Triphosphate Diphosphohydrolase-1
FDA	Federal Drug Administration
GI	Gastrointestinal
GM-CSF	Granulocyte-Macrophage Colony-Stimulating Factor
GoG	Gynecologic Oncology Group
G + C	Gemcitabine plus Cisplatin
HDR	High Dose Rate
HLA-A	Human Leukocyte Antigen
HPV	Human Papillomavirus
HR	Hazard Ratio
HRD	Homologous Recombination Deficiency
hrHPV	High-Risk HPV
HRP	Homologous Recombination Proficient
IFNs	Interferons
irAE	Immune-Related Adverse Events
LCs	Langerhans Cells
LDR	Low Dose Rate
LVSI	Lymph-Vascular Space Invasion
MCP	Monocyte chemoattractant protein
mDOR	Median Duration of Response
NR	Not Reached
ORR	Operational Readiness Review
OS	Overall Survival
Pap smear	Papanicolaou Test
PD-1	Programmed Death-1
PD-1L	Programmed Death-Ligand 1
PFS	Progression-Free Survival
PST	Prior Systemic Therapy
P + C	Paclitaxel plus Cisplatin
p53	Tumor Protein
QOL	Quality of Life
RFS	Recurrence-Free Survival
RMST	Restricted Mean Survival Time
RT	Radiation Therapy
RTOG	Radiation Therapy Oncology Group
SEER	Surveillance, Epidemiology, and End Results
STI	Sexually Transmitted Infection
TAMs	Tumor-Associated Macrophages
TCR	T-Cell Receptor
TGF-β	Transforming Growth Factor Beta
TLRs	Toll-Like Receptors
TRAEs	Treatment-Related Adverse Events
Tivdak	Tisotumab Vedotin
TPZ	Tirapazamine
T + C	Topotecan plus Cisplatin
US	United States
USPSTF	United States Preventative Services Taskforce
WHO	World Health Organization
WPRT	Whole Pelvis Radiation Therapy
VEGFR	Vascular Endothelial Growth Factor Receptor
VEGF-A	Vascular Endothelial Growth Factor-A
VLP	Virus-Like Particles
V + C	Vinorelbine plus Cisplatin